JP2021525534A5 - - Google Patents
Info
- Publication number
- JP2021525534A5 JP2021525534A5 JP2020567215A JP2020567215A JP2021525534A5 JP 2021525534 A5 JP2021525534 A5 JP 2021525534A5 JP 2020567215 A JP2020567215 A JP 2020567215A JP 2020567215 A JP2020567215 A JP 2020567215A JP 2021525534 A5 JP2021525534 A5 JP 2021525534A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- amino acid
- identity
- polypeptide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189072A JP7827673B2 (ja) | 2018-06-04 | 2023-11-06 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2025184908A JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680297P | 2018-06-04 | 2018-06-04 | |
| US62/680,297 | 2018-06-04 | ||
| PCT/US2019/035384 WO2019236577A2 (en) | 2018-06-04 | 2019-06-04 | Muc16 specific chimeric antigen receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189072A Division JP7827673B2 (ja) | 2018-06-04 | 2023-11-06 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525534A JP2021525534A (ja) | 2021-09-27 |
| JP2021525534A5 true JP2021525534A5 (https=) | 2022-05-30 |
Family
ID=68764543
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Pending JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2023189072A Active JP7827673B2 (ja) | 2018-06-04 | 2023-11-06 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2025184908A Pending JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189072A Active JP7827673B2 (ja) | 2018-06-04 | 2023-11-06 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2025184908A Pending JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11319380B2 (https=) |
| EP (1) | EP3802615A4 (https=) |
| JP (3) | JP2021525534A (https=) |
| KR (1) | KR20210021493A (https=) |
| CN (2) | CN112533957B (https=) |
| AU (1) | AU2019282620B2 (https=) |
| CA (1) | CA3101641A1 (https=) |
| IL (1) | IL278976A (https=) |
| SG (1) | SG11202011895VA (https=) |
| WO (1) | WO2019236577A2 (https=) |
| ZA (3) | ZA202008065B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11771718B2 (en) * | 2017-10-18 | 2023-10-03 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| AU2019372673A1 (en) * | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| US20230257705A1 (en) * | 2020-06-17 | 2023-08-17 | Kyoto University | Chimeric antigen receptor-expressing immunocompetent cells |
| KR20230122618A (ko) * | 2020-12-21 | 2023-08-22 | 알로젠 테라퓨틱스 인코포레이티드 | 프로테아제 활성화 cd45-게이트 car |
| CN116648457A (zh) * | 2020-12-31 | 2023-08-25 | 亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫细胞中的应用 |
| US20220133801A1 (en) * | 2021-01-19 | 2022-05-05 | Obsidian Therapeutics, Inc. | Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancer |
| KR20230147619A (ko) * | 2021-02-26 | 2023-10-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 외인적으로 도입된 사이토카인을 발현하는 조작된 면역이펙터 세포 |
| US20250145950A1 (en) * | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN115819613B (zh) * | 2022-05-10 | 2023-10-20 | 四川大学华西医院 | 基于msln前体蛋白构建的嵌合抗原受体免疫细胞制备及其应用 |
| CN116196402A (zh) * | 2022-11-01 | 2023-06-02 | 山东大学齐鲁医院 | 表达双特异性抗体的溶瘤腺病毒联合cart在肿瘤治疗中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| PL2135881T3 (pl) | 2005-06-20 | 2012-02-29 | Genentech Inc | Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| WO2009088105A1 (en) | 2008-01-11 | 2009-07-16 | Gene Techno Science Co., Ltd. | HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF |
| TR201904484T4 (tr) * | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| CA3255551A1 (en) * | 2010-03-26 | 2025-04-15 | Memorial Sloan-Kettering Cancer Center | MUC16 ANTIBODIES AND METHODS OF USE |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CN106795221B (zh) * | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| WO2016160618A2 (en) | 2015-03-27 | 2016-10-06 | University Of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| CN108064246A (zh) | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| CA2997551A1 (en) | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| CA3025667A1 (en) * | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| JP2019524706A (ja) * | 2016-07-08 | 2019-09-05 | ジェネンテック， インコーポレイテッド | Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用 |
| US12304935B2 (en) | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| JP7050770B2 (ja) * | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| CN107557336B (zh) * | 2017-09-15 | 2020-02-14 | 山东兴瑞生物科技有限公司 | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 |
-
2019
- 2019-06-04 US US16/431,193 patent/US11319380B2/en active Active
- 2019-06-04 SG SG11202011895VA patent/SG11202011895VA/en unknown
- 2019-06-04 KR KR1020207038033A patent/KR20210021493A/ko active Pending
- 2019-06-04 CN CN201980052129.8A patent/CN112533957B/zh active Active
- 2019-06-04 CN CN202610008767.1A patent/CN121852427A/zh active Pending
- 2019-06-04 JP JP2020567215A patent/JP2021525534A/ja active Pending
- 2019-06-04 EP EP19815389.2A patent/EP3802615A4/en active Pending
- 2019-06-04 CA CA3101641A patent/CA3101641A1/en active Pending
- 2019-06-04 WO PCT/US2019/035384 patent/WO2019236577A2/en not_active Ceased
- 2019-06-04 AU AU2019282620A patent/AU2019282620B2/en active Active
-
2020
- 2020-11-25 IL IL278976A patent/IL278976A/en unknown
- 2020-12-23 ZA ZA2020/08065A patent/ZA202008065B/en unknown
-
2021
- 2021-12-22 ZA ZA2021/10780A patent/ZA202110780B/en unknown
-
2022
- 2022-02-04 US US17/650,025 patent/US11976134B2/en active Active
- 2022-02-04 US US17/650,018 patent/US11981746B2/en active Active
-
2023
- 2023-11-06 JP JP2023189072A patent/JP7827673B2/ja active Active
- 2023-12-19 ZA ZA2023/11718A patent/ZA202311718B/en unknown
-
2024
- 2024-04-05 US US18/628,575 patent/US20240368305A1/en active Pending
-
2025
- 2025-10-31 JP JP2025184908A patent/JP2026031977A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525534A5 (https=) | ||
| JP2024138280A5 (https=) | ||
| US12371470B2 (en) | Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen | |
| JP2021530217A5 (https=) | ||
| JP7574243B2 (ja) | 抗ｃｄ７０キメラ抗原受容体 | |
| JP6970991B2 (ja) | トランスポザーゼポリペプチド及びその使用 | |
| JP2019517267A5 (https=) | ||
| TWI811278B (zh) | 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞 | |
| JP2024023232A5 (https=) | ||
| JP2020521462A (ja) | 形質転換されたｔ細胞を用いてナチュラルキラー細胞を培養する方法 | |
| KR20150003306A (ko) | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 | |
| KR20180057723A (ko) | 항-cd30 키메라성 항원 수용체 | |
| JP2020120660A (ja) | キメラ抗原受容体 | |
| CN113881694A (zh) | 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体 | |
| WO2022029431A1 (en) | Chimeric receptor binding tgf-beta | |
| JP2025512886A (ja) | キメラサイトカイン受容体 | |
| KR20220087431A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| KR20220040489A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| KR20220038776A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| JP2026506591A (ja) | 天然タンパク質ｔｓｈを抗原結合部位とした、ｔｓｈｒを標的とするｃａｒ－ｔ細胞の構築 | |
| RU2023106937A (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения | |
| KR20250174161A (ko) | 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도 | |
| CN121693513A (zh) | TGFβ转换受体、编码它的核酸、细胞和包含它的药物组合物 | |
| KR20260052956A (ko) | TGFβ 스위치 수용체, 이를 코딩하는 핵산, 이를 포함하는 세포 및 약학 조성물 |